This post was originally published on this site Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a way to improve the treatment decision process for ovarian cancer. Despite the advances made to improve diagnosis…
This post was originally published on this site To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to establish a “gold standard” immune profiling platform for multiple myeloma research studies, and to produce the kind of…
This post was originally published on this site Triumvira Immunulogics is launching a Phase 1/2 clinical trial to test its T-cell therapy candidate, TAC01-CD19, in patients with B-cell lymphoma across the U.S. and Canada, the company announced. The TACTIC-19 trial (NCT03880279), set to begin in a few months, comes after the U.S Food and Drug…
This post was originally published on this site PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a second generation fluorine-labeled small molecule that…
This post was originally published on this site Syntrix Pharmaceuticals has dosed the first patient in an ongoing Phase 1/2 clinical trial testing its experimental therapy SX-682 in combination with Keytruda (pembrolizumab) as a treatment for advanced melanoma, the company announced. The open-label trial (NCT03161431) is being conducted at the Massachusetts General Hospital Cancer Center and…
This post was originally published on this site Combining Ibrance (palbociclib), a treatment for advanced breast cancer, with the lung cancer medicine crizotinib is more effective against human cancer cells in the laboratory than either drug alone, scientists have found. The researchers say the findings suggest the combination could be used to overcome treatment resistance in some…
This post was originally published on this site CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate Cancer: Managing Cardiovascular Risk,” the nine-episode series features Andy Rochester, a prostate cancer survivor, discussing his experiences with Susan F.…
This post was originally published on this site A new collaborative project seeks to help ovarian cancer programs better understand and remove impediments to optimal care for patients with advanced epithelial disease. Called “Barriers to Quality Care in Ovarian Cancer,” the effort will be led by the Association of Community Cancer Centers (ACCC), along with AstraZeneca…
This post was originally published on this site Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results of a Phase 2 clinical trial. The open-label GRIFFIN study (NCT02874742) includes 223 patients eligible for high-dose chemotherapy…
This post was originally published on this site NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows the U.S. Food and Drug Administration‘s approval of NantKwest’s investigational new drug (IND) application for the therapy. Natural…
